REGENERON PHARMACEUTICALS, INC. (REGN) Return on equity 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.4%FY2025 · since FY2016: 20.1% → 14.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.4% | -0.6 pp |
| FY2024 | 15.0% | -0.2 pp |
| FY2023 | 15.2% | -3.9 pp |
| FY2022 | 19.1% | -23.9 pp |
| FY2021 | 43.0% | +11.2 pp |
| FY2020 | 31.9% | +12.8 pp |
| FY2019 | 19.1% | -8.8 pp |
| FY2018 | 27.9% | +8.4 pp |
| FY2017 | 19.5% | -0.6 pp |
| FY2016 | 20.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More REGN financial trends
REGN RevenueREGN Net incomeREGN Net marginREGN Gross profitREGN Gross marginREGN Operating incomeREGN Operating marginREGN Operating cash flowREGN Free cash flowREGN Capital expendituresREGN Stock buybacksREGN Dividends paidREGN Total assetsREGN Total liabilitiesREGN Shareholders’ equityREGN overview →